Clinical significance of caspase-3 expression in pathologic-stage I, nonsmall-cell lung cancer

✍ Scribed by Tetsuya Takata; Fumihiro Tanaka; Tomoko Yamada; Kazuhiro Yanagihara; Yosuke Otake; Yozo Kawano; Tatsuo Nakagawa; Ryo Miyahara; Hiroki Oyanagi; Kenji Inui; Hiromi Wada

• Publisher: John Wiley and Sons
• Year: 2001
• Tongue: French
• Weight: 114 KB
• Volume: 96
• Category: Article
• ISSN: 0020-7136
• DOI: 10.1002/ijc.10347

✦ Synopsis

Caspase-3 is a cysteine protease that plays an important role in the process of apoptotic cell death. Whereas many studies on the clinical significance of apoptosis in the therapy of malignant tumors have been reported, little has been studied clinically on caspase-3. In the present study, the clinical significance of caspase-3 expression in resected nonsmall-cell lung cancer (NSCLC) and its correlation with incidence of apoptosis were examined. A total of 118 consecutive patients who had undergone complete resection for pathologic Stage I NSCLC were retrospectively reviewed. Caspase-3 expression was examined immunohistochemically using a polyclonal antibody that recognized uncleaved caspase-3. The 5-year survival rate for patients with strong expression of caspase-3 (66.6%) was significantly lower than that for patients with weak expression (82.1%, P ‫؍‬ 0.021). Expression of caspase-3 was not correlated with incidence of apoptosis, proliferative activity, or p53 status. Multivariate analysis confirmed that strong expression of caspase-3 was a significant factor to predict poor prognosis. These results suggest that enhanced expression of "uncleaved" caspase-3, that is, inactivated caspase-3, was correlated with poor prognosis in resected NSCLC.